Patents by Inventor Thomas H. McLean

Thomas H. McLean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230353959
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 2, 2023
    Inventors: Lucian V. DIPIETRO, Kelley C. SHORTSLEEVES, Thomas H. MCLEAN, Alexandre LARIVEE, Fabrizio GIORDANETTO
  • Publication number: 20230234958
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: December 15, 2022
    Publication date: July 27, 2023
    Inventors: Alexander M. Taylor, Andre Lescarbbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • Publication number: 20230104574
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 12, 2020
    Publication date: April 6, 2023
    Inventors: Bakary-Barry TOURÉ, Heike SCHOENHERR, Alexander M. TAYLOR, Fabrizio GIORDANETTO, Demetri T. MOUSTAKAS, Thomas H. MCLEAN, Brandi M. HUDSON, Mary M. MADER, Pelin AYAZ, Dina A. SHARON, Ravi KURUKULASURIYA, Alessandro BOEZIO
  • Publication number: 20230056447
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: September 14, 2021
    Publication date: February 23, 2023
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. Mclean
  • Publication number: 20220356184
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: March 23, 2021
    Publication date: November 10, 2022
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Publication number: 20220340576
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: November 17, 2020
    Publication date: October 27, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • Publication number: 20220315586
    Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Application
    Filed: March 21, 2019
    Publication date: October 6, 2022
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Thomas H. McLean, Hakan Gunaydin, Fabrizio Giordanetto, Eric Therrien
  • Patent number: 11396508
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 26, 2022
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Publication number: 20220073527
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventors: Jeremy Robert GREENWOOD, Geraldine C. HARRIMAN, Silvana M. LEIT DE MORADEI, Craig E. MASSE, Thomas H. MCLEAN, Sayan MONDAL
  • Patent number: 11220508
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 11, 2022
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit De Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 11174265
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: November 16, 2021
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit De Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Publication number: 20210230163
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 29, 2021
    Inventors: Jeremy Robert GREENWOOD, Geraldine C. HARRIMAN, Silvana Marcel LEIT DE MORADEI, Craig E. MASSE, Thomas H. MCLEAN, Sayan MONDAL
  • Patent number: 11046698
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: June 29, 2021
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Publication number: 20210094948
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Application
    Filed: February 28, 2020
    Publication date: April 1, 2021
    Inventors: Jeremy Robert Greenwood, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 10793574
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 6, 2020
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 10647713
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: May 12, 2020
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 10577373
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 3, 2020
    Assignee: Nimbus Lakshimi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Patent number: 10570145
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 25, 2020
    Assignee: Nimbus Lakshimi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Patent number: 10562906
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 18, 2020
    Assignee: Nimbus Lakshimi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean
  • Patent number: 10562907
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: February 18, 2020
    Assignee: Nimbus Lakshimi, Inc.
    Inventors: Craig E. Masse, Jeremy Robert Greenwood, Sayan Mondal, Scott D. Cowen, Thomas H. McLean